Signaling	NN
pathways	NNS
in	IN
the	DT
epithelial	JJ
origins	NNS
of	IN
pulmonary	JJ
fibrosis	NN
.	.

Pulmonary	JJ
fibrosis	NN
complicates	VBZ
a	DT
number	NN
of	IN
disease	NN
processes	NNS
and	CC
leads	VBZ
to	TO
substantial	JJ
morbidity	NN
and	CC
mortality	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
perhaps	RB
the	DT
most	RBS
pernicious	JJ
and	CC
enigmatic	JJ
form	NN
of	IN
the	DT
greater	JJR
problem	NN
of	IN
lung	NN
fibrogenesis	NN
with	IN
a	DT
median	JJ
survival	NN
of	IN
three	CD
years	NNS
from	IN
diagnosis	NN
in	IN
affected	JJ
patients	NNS
.	.

In	IN
this	DT
review	NN
,	,
we	PRP
will	MD
focus	VB
on	IN
the	DT
pathology	NN
of	IN
IPF	NN
as	IN
a	DT
model	NN
of	IN
pulmonary	JJ
fibrotic	JJ
processes	NNS
,	,
review	NN
possible	JJ
cellular	JJ
mechanisms	NNS
,	,
review	NN
current	JJ
treatment	NN
approaches	NNS
and	CC
review	VB
two	CD
transgenic	JJ
mouse	NN
models	NNS
of	IN
lung	NN
fibrosis	NN
to	TO
provide	VB
insight	NN
into	IN
processes	NNS
that	WDT
cause	VBP
lung	NN
fibrosis	NN
.	.

We	PRP
will	MD
also	RB
summarize	VB
the	DT
potential	JJ
utility	NN
of	IN
signaling	NN
pathway	NN
inhibitors	NNS
as	IN
a	DT
future	JJ
treatment	NN
in	IN
pulmonary	JJ
fibrosis	NN
.	.

Finally	RB
,	,
we	PRP
will	MD
present	VB
data	NNS
demonstrating	VBG
a	DT
minimal	JJ
contribution	NN
of	IN
epithelial-mesenchymal	JJ
transition	NN
in	IN
the	DT
development	NN
of	IN
fibrotic	JJ
lesions	NNS
in	IN
the	DT
transforming	VBG
growth	NN
factor-alpha	NN
transgenic	JJ
model	NN
of	IN
lung	NN
fibrosis	NN
.	.

